Fresenius Kabi is entering a German adalimumab market in which Amgen, Mylan and Sandoz are already competing against AbbVie’s Humira reference brand. In this environment, Fresenius’ sales expectations are modest.

Fresenius Kabi has become the latest firm to receive a nod for a European biosimilar rival to Humira, adding to an already crowded biosimilar adalimumab market.

Positive measures including a drive to increase uptake of biosimilars are offset by more negative aspects, such as promoting pharmacy substitution of biologics and exposing cytostatic cancer therapies to tender processes, under draft medicines legislation unveiled by Germany’s ministry of health.